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BACKGROUND 
In 2016, the Legislature enacted Public Law 2015, Chapter 488, “An Act to Prevent Opiate Abuse by 
Strengthening the Controlled Substances Prescription Monitoring Program.” This statute established 
limits on both the duration and dosage of prescriptions which health care providers may write for opioid 
medications.  Section 38 tasks the Bureau of Insurance with studying the effects of this legislation on 
claims paid by health carriers and the out-of-pocket costs (coinsurance, copayments and deductibles) 
paid by policy holders and certificate holders: 
Sec. 38. Effect on out-of-pocket costs. The Bureau of Insurance within the Department of 
Professional and Financial Regulation shall evaluate the effect of the limits on prescriptions for opioid 
medication established by this Act on the claims paid by health insurance carriers and the out-of-pocket 
costs, including copayments, coinsurance and deductibles, paid by individual and group health insurance 
policyholders. On or before January 1, 2018, the bureau shall submit a report on the evaluation, along 
with any recommended policy and regulatory options that will ensure costs for patients are not increased 
as a result of new prescribing limitations on the amounts of opioid medications, to the joint standing 
committees of the Legislature having jurisdiction over health and human services matters and over 
insurance and financial services matters. The joint standing committee of the Legislature having 
jurisdiction over health and human services matters and the joint standing committee of the Legislature 
having jurisdiction over insurance and financial services matters may report out legislation related to the 
evaluation to the Second Regular Session of the 128th Legislature. 
Public Law Chapter 488 is attached as Appendix 1 of this report. 
PROCESS 
The Bureau held a stakeholder meeting on October 31, 2016 to determine the types of data to be 
reviewed to meet the requirements in the statute.   
Prior to this meeting, the Bureau requested a copy of each insurance company’s policy on opioids and 
their derivatives for prescription allowances, including their formularies, and any formulary 
requirements, such as prescription limits and prior authorizations.  This information was requested for 
individual, small group and large group fully-funded plans in Maine, and was utilized to determine which 
medications needed to be reported.  Through this process, the Bureau determined that all carriers 
enforced quantity limits on chronic pain medications and required prior authorization for certain 
medications, and their formularies included abuse deterrent forms of the medications. 
The stakeholder meeting included representatives from  
• Aetna  
• American Cancer Society/Maine Cancer Action Network 
• Anthem 
• CIGNA  
• Community Health Options 
• Consumers for Affordable Health Care 
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• Harvard Pilgrim Health Care 
• Maine Health Data Organization 
• Maine Medical Association 
• Maine Quality Counts 
• United Healthcare.  
MAINE HEALTH DATA ORGANIZATION DATA 
The Bureau and the stakeholders agreed that the Maine Health Data Organization‘s (MHDO) all-payer, 
all-claims database could provide a summary of total carrier members with opioid prescriptions, opioid 
claims, total carrier payments and total member payments.  It was determined that the data for the full 
year of 2017 would not be available in time to analyze data for the purposes of this report.  Information 
regarding the first two quarters of 2017 was not expected to be available until October 2017.  Therefore, 
to provide a comparative analysis, only the first two quarters of 2016 were reviewed and used in this 
report.  This data is available in Appendix 2. 
The Federal Center for Disease Control (CDC) maintains a National Drug Code (NDC) file for Morphine 
Milliequivalents (MME’s) with Opioids.  Data from that file was also utilized in this report.1   
Twenty-four companies submitted data for the first and second quarters of 2016 and 2017 for this 
report.  Company information derived from pharmacy benefit managers, payers and third party 
administrators was utilized. A list of the companies is provided in Appendix 3. 
Pursuant to Public Law 2015 Chapter 488, data analyzed in this report excludes data from Medicare and 
Medicaid.  It further excludes the exceptions listed in Public Law 2015 Ch. 488, specifically: 
 A.  When prescribing opioid medication to a patient for: 
(1) Pain associated with active and aftercare cancer treatment; 
(2) Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph A, in conjunction 
with a serious illness, as defined in Title 22, section 1726, subsection 1, paragraph B; 
(3) End-of-life and hospice care; 
(4) Medication-assisted treatment for substance use disorder; or 
(5) Other circumstances determined in rule by the Department of Health and Human Services 
pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering, or administering a benzodiazepine or opioid medication to a person in an 
emergency room setting, an inpatient hospital setting, a long-term care facility or a residential care 
facility. 
                                                          
1 Changes in the reporting to CDC or in the NDC’s file could affect the data, as certain classes of opioids 
may have been missed in the gathering of the data.     
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The data is an aggregate of all carriers and all claims as provided by the Maine Health Data Organization 
(MHDO).  However, the time for prescription claims to be submitted to carriers (run-off period) and 
subsequently reported to MHDO by carriers could differ due to differences in pharmacy settings; this 
could possibly affect the validity of the data.  Quarter one of 2016 reflects a nine-month run-off.  
Quarter two of 2016 data had a six-month run-off.  By contrast, because MHDO 2017 data is reported 
only through June 30, 2017, quarter one of 2017 data reflects only a three-month run-off and quarter 
two data has no run-off.  Although 2017 data used in this report does not reflect late-submitted claims 
on the same basis as 2016 data, the Bureau’s judgment is that the effect of this variance on results is 
minimal because it is the Bureau’s experience that most pharmacies submit claims promptly.   
 
FINDINGS 
Table 1 outlines the number of unduplicated members whose plans include pharmacy benefits, with 
prescription claims for each quarter (column 1), and with claims specifically for opioids and opioid 
derivatives (column 2).  Overall, there were 1.5% fewer members with opioid prescription claims in the 
first half of 2017 compared to 2016.  
Table 1 – Pharmacy Members with Claims 
 Pharmacy Members with 
All Types of Prescription 
Claims 
Pharmacy members with 
Opioid Prescription 
Claims 
Percentage of 
prescriptions for 
opioid medications 
Quarter 1 2016 333,767 34,056 10.2% 
Quarter 2 2016 302,495 29,727 9.8% 
Overall Q1 & Q2 2016 393,434 51,253 13% 
Quarter 1 2017 300,359 26,512 8.8% 
Quarter 2 2017 293,394 24,091 8.2% 
Overall Q1 & Q2 2017 354,232 40,591 11.5% 
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Table 2 compares opioid prescription claims by quarter.  It shows an overall decrease in opioid 
prescription claims of 19.8%.  This number could reflect many factors which would require prescriber 
clarification, but could include: providers weaning patients’ dosages; adherence to prescription limits; or 
uses of alternative pain treatments, such as physical therapy, massage or other alternative treatments.  
Information about these potential factors is not available and would be difficult to measure.  
Table 2 - Counts of Opioid Claims   
 2016 2017 Difference  
 
Percentage 
Q1  75,466 58,631 - 16,835 -22.4% 
Q 2 64,300 53,389 -10,911 -17% 
Overall  139,754 112,015 -27,739 -19.8% 
 
Table 3 shows the amounts paid by the carriers and consumers for all opioid claims in the first two 
quarters of 2016 and 2017.     
Table 3 – Dollars Paid for Opioid Claims 
 Total Carriers Paid Total Members paid Overall total 
Q1 2016 $2,811,997.42 $923,758.74 $3,735,756.16 
Q2 2016 $2,444,551.02 $644,609.79 $3,089,170.81 
Overall Q1 & Q2 2016 $5,256,548.44 $1,568,368.53 $6,824,916.97 
Q1 2017 $1,452,072.35 $555,736.52 $2,007,808.87 
Q2 2017 $1,351,184.42 $433,248.11 $1,784,432.53 
Overall Q1 & Q2 2017 $2,803,256.77 $988,984.63 $3,792,241.40 
 
Table 4 compares the cost per year (based on the first two quarters of each year) of the cost paid out by 
insurance plans for opioid related claims.  Carriers had an average cost of $37.61 per opioid claim in the 
first two quarters of 2016 and $25.03 per claim in the first two quarters of 2017.  The variance in the 
cost may be a result of the prescription limits from 90 days to 30 days, but this cannot be determined 
based on the data used in this report.   
Table 4 – Dollars Spent by Payers for Opioid Claims 
 2016 2017 Difference Percentage 
Q1 & Q2 $5,256,548.44 $2,803,256.77 $2,453,291.67 -46.7% 
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Table 5 outlines the decrease in consumer cost-sharing of opioid related prescription costs (deductibles, 
copayments and coinsurance).  As is the case with all the tables in this report, this data is an aggregate 
of all carriers and all claims as provided by the Maine Health Data Organization (MHDO).  On average, 
consumers paid $11.22 per claim in the first two quarters of 2016 and $8.83 per claim in the first two 
quarters of 2017.  Again, the variance in the cost may be a result of adherence to prescription limits 
from 90 days to 30 days, but that cannot be determined from data used for this report.   
Table 5 – Cost-sharing Dollars Spent by Members 
 2016 2017 Difference Percentage 
Q1 & Q2 $1,568,368.53 $988,984.63 $579,383.90 -36.9% 
  
CONCLUSIONS 
In summary, the Bureau’s analysis of the Maine Health Data Organization’s data for the first two 
quarters of 2016 and 2017 indicates the following: 
• The number of members with prescriptions for opioids and opioid derivatives decreased from 
51,253 in the first half of 2016 to 40,591 in the first half of 2017, a drop of over 10,000 members 
with these prescriptions. 
• The number of prescription claims for opioids and opioid derivatives decreased 19.8%, with 
27,739 fewer claims between the first half 2016 and the first half of 2017.  
• Insurance carriers spent more than $2.4 million less (46.7%) on opioid and opioid derivative 
claims in the first half of 2017 than in the first half of 2016. 
• Plan members spent nearly $580,000 less (36.9%) in cost-sharing for opioid and opioid 
derivative claims in the first half of 2017 than in the first half of 2016.   
 
Because these findings indicate decreases in the number of claims, the dollars spent by carriers, and the 
cost-sharing paid by members, the Bureau does not have any recommendations regarding policy and 
regulatory options that will ensure that costs for patients are not increased as a result of new 
prescribing limitations on the amounts of opioid medications.   
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STATE OF MAINE 
_____ 
IN THE YEAR OF OUR LORD 
TWO THOUSAND AND SIXTEEN 
_____ 
S.P. 671 - L.D. 1646 
An Act To Prevent Opiate Abuse by Strengthening the Controlled 
Substances Prescription Monitoring Program 
Be it enacted by the People of the State of Maine as follows: 
Sec. 1.  22 MRSA §7246, sub-§§1-A, 1-B and 1-C are enacted to read: 
1-A.  Acute pain.  "Acute pain" means pain that is the normal, predicted 
physiological response to a noxious chemical or thermal or mechanical stimulus.  "Acute 
pain" typically is associated with invasive procedures, trauma and disease and is usually 
time-limited. 
1-B.  Administer.  "Administer" means an action to apply a prescription drug
directly to a person by any means by a licensed or certified health care professional acting 
within that professional's scope of practice.  "Administer" does not include the delivery, 
dispensing or distribution of a prescription drug for later use. 
1-C.  Chronic pain.  "Chronic pain" means pain that persists beyond the usual course
of an acute disease or healing of an injury.  "Chronic pain" may or may not be associated 
with an acute or chronic pathologic process that causes continuous or intermittent pain 
over months or years. 
Sec. 2.  22 MRSA §7246, sub-§5, as enacted by PL 2003, c. 483, §1, is amended 
to read: 
5. Prescriber.  "Prescriber" means a licensed health care professional with authority
to prescribe controlled substances and a veterinarian licensed under Title 32, chapter 
71-A with authority to prescribe controlled substances. 
Sec. 3.  22 MRSA §7249, sub-§4, as enacted by PL 2003, c. 483, §1, is amended 
to read: 
4. Immunity from liability.  A dispenser or prescriber is immune from liability for
disclosure of information if the disclosure was made pursuant to and in accordance with 
this chapter. 
APPROVED 
APRIL 19, 2016 
BY GOVERNOR 
CHAPTER 
488 
PUBLIC LAW 
APPENDIX 1
  Page 2 - 127LR2717(04)-1 
 
Sec. 4.  22 MRSA §7250, sub-§4, ¶G, as amended by PL 2011, c. 657, Pt. O, §3, 
is further amended to read: 
G.  The office that administers the MaineCare program pursuant to chapter 855 for 
the purposes of managing the care of its members, monitoring the purchase of 
controlled substances by its members, avoiding duplicate dispensing of controlled 
substances and providing treatment pattern data under subsection 6; and 
Sec. 5.  22 MRSA §7250, sub-§4, ¶H, as enacted by PL 2011, c. 218, §3, is 
amended to read: 
H.  Another state or a Canadian province pursuant to subsection 4-A.; 
Sec. 6.  22 MRSA §7250, sub-§4, ¶¶I and J are enacted to read: 
I.  Staff members of a licensed hospital who are authorized by the chief medical 
officer of the hospital, insofar as the information relates to a patient receiving care in 
the hospital's emergency department or receiving inpatient services from the hospital; 
and 
J.  Staff members of a pharmacist who are authorized by the pharmacist on duty, 
insofar as the information relates to a customer seeking to have a prescription filled. 
Sec. 7.  22 MRSA §7250, sub-§4-A, as amended by PL 2011, c. 657, Pt. AA, 
§69, is further amended to read: 
4-A.  Information sharing with other states and Canadian provinces.  The 
department may provide prescription monitoring information to and receive prescription 
monitoring information from another state or a Canadian province that has prescription 
monitoring information provisions consistent with this chapter and has entered into a 
prescription monitoring information sharing agreement with the department.  The 
department may enter into a prescription monitoring information sharing agreement with 
another state or a Canadian province to establish the terms and conditions of prescription 
monitoring information sharing and interoperability of information systems and to carry 
out the purposes of this subsection.  For purposes of this subsection, "another state" 
means any state other than Maine and any territory or possession of the United States, but 
does not include a foreign country. 
Sec. 8.  22 MRSA §7251, sub-§1, as amended by PL 2011, c. 657, Pt. AA, §70, is 
further amended to read: 
1.  Failure to submit information.  A dispenser who knowingly fails to submit 
prescription monitoring information to the department as required by this chapter 
commits a civil violation for which a fine of $250 per incident, not to exceed $5,000 per 
calendar year, may be adjudged and is subject to discipline by the Maine Board of 
Pharmacy pursuant to Title 32, chapter 117, subchapter 4 or by the applicable 
professional licensing entity. 
Sec. 9.  22 MRSA §§7253 and 7254 are enacted to read: 
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§7253.  Prescribers and dispensers required to check prescription monitoring 
information 
1.  Prescribers.  On or after January 1, 2017, upon initial prescription of a 
benzodiazepine or an opioid medication to a person and every 90 days for as long as that 
prescription is renewed, a prescriber shall check prescription monitoring information for 
records related to that person. 
2.  Dispensers.  On or after January 1, 2017, a dispenser shall check prescription 
monitoring information prior to dispensing a benzodiazepine or an opioid medication to a 
person under any of the following circumstances: 
A.  The person is not a resident of this State; 
B.  The prescription is from a prescriber with an address outside of this State; 
C.  The person is paying cash when the person has prescription insurance on file; or 
D.  According to the pharmacy prescription record, the person has not had a 
prescription for a benzodiazepine or an opioid medication in the previous 12-month 
period. 
A dispenser shall notify the program and withhold a prescription until the dispenser is 
able to contact the prescriber of that prescription if the dispenser has reason to believe 
that the prescription is fraudulent or duplicative. 
3.  Exception; hospital setting and facilities.  When a licensed or certified health 
care professional directly orders or administers a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility, the requirements to check prescription monitoring 
information established in this section do not apply. 
4.  Violation.  A person who violates this section commits a civil violation for which 
a fine of $250 per incident, not to exceed $5,000 per calendar year, may be adjudged. 
5.  Rulemaking.  Notwithstanding section 7252, the department may adopt routine 
technical rules as defined in Title 5, chapter 375, subchapter 2-A to implement this 
section. 
§7254.  Exemption from opioid medication limits until January 2017; rulemaking 
1.  Exemption until January 2017.  In addition to the exceptions established in Title 
32, section 2210, subsection 2; section 2600-C, subsection 2; section 3300-F, subsection 
2; section 3657, subsection 2; and section 18308, subsection 2, a licensed health care 
professional may prescribe opioid medication in an amount greater than the morphine 
milligram equivalents limited by Title 32, sections 2210, 2600-C, 3300-F, 3657 and 
18308 as long as it is medically necessary and the need is documented in the patient's 
chart. 
This subsection is repealed January 1, 2017 or on the effective date of the rules 
establishing exceptions to prescriber limits as provided in subsection 2, whichever is 
later.  The Commissioner of Health and Human Services shall notify the Secretary of 
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State, Secretary of the Senate, Clerk of the House of Representatives and Revisor of 
Statutes of this effective date when this effective date is determined. 
2.  Rulemaking.  Notwithstanding section 7252, no later than January 1, 2017, the 
department shall adopt routine technical rules as defined in Title 5, chapter 375, 
subchapter 2-A to establish reasonable exceptions to prescriber limits in Title 32, sections 
2210, 2600-C, 3300-F, 3657 and 18308, including for chronic pain and acute pain.  The 
rules must take into account clinically appropriate exceptions and include prescribers in 
the rule-making process including the drafting of draft rules and changes after the public 
hearing process to the extent permitted by Title 5, chapter 375. 
Sec. 10.  32 MRSA §2105-A, sub-§2, ¶H, as amended by PL 1993, c. 600, Pt. A, 
§116, is further amended to read: 
H.  A violation of this chapter or a rule adopted by the board; or 
Sec. 11.  32 MRSA §2105-A, sub-§2, ¶I, as enacted by PL 1983, c. 378, §21, is 
amended to read: 
I.  Engaging in false, misleading or deceptive advertising.; or 
Sec. 12.  32 MRSA §2105-A, sub-§2, ¶J is enacted to read: 
J.  Failure to comply with the requirements of Title 22, section 7253. 
Sec. 13.  32 MRSA §2210 is enacted to read: 
§2210.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  Except as provided in subsection 2, 
an individual licensed under this chapter whose scope of practice includes prescribing 
opioid medication may not prescribe: 
A.  To a patient any combination of opioid medication in an aggregate amount in 
excess of 100 morphine milligram equivalents of opioid medication per day; 
B.  To a patient who, on the effective date of this section, has an active prescription 
for opioid medication in excess of 100 morphine milligram equivalents of an opioid 
medication per day, an opioid medication in an amount that would cause that patient's 
total amount of opioid medication to exceed 300 morphine milligram equivalents of 
opioid medication per day; except that, on or after July 1, 2017, the aggregate amount 
of opioid medication prescribed may not be in excess of 100 morphine milligram 
equivalents of opioid medication per day; 
C.  On or after January 1, 2017, within a 30-day period, more than a 30-day supply of 
an opioid medication to a patient under treatment for chronic pain.  "Chronic pain" 
has the same meaning as in Title 22, section 7246, subsection 1-C; or 
D.  On or after January 1, 2017, within a 7-day period, more than a 7-day supply of 
an opioid medication to a patient under treatment for acute pain.  "Acute pain" has the 
same meaning as in Title 22, section 7246, subsection 1-A. 
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2.  Exceptions.  An individual licensed under this chapter whose scope of practice 
includes prescribing opioid medication is exempt from the limits on opioid medication 
prescribing established in subsection 1 only: 
A.  When prescribing opioid medication to a patient for: 
(1)  Pain associated with active and aftercare cancer treatment; 
(2)  Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph 
A, in conjunction with a serious illness, as defined in Title 22, section 1726, 
subsection 1, paragraph B; 
(3)  End-of-life and hospice care; 
(4)  Medication-assisted treatment for substance use disorder; or 
(5)  Other circumstances determined in rule by the Department of Health and 
Human Services pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering or administering a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility. 
As used in this paragraph, "administer" has the same meaning as in Title 22, section 
7246, subsection 1-B. 
3.  Electronic prescribing.  An individual licensed under this chapter whose scope of 
practice includes prescribing opioid medication and who has the capability to 
electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  An individual who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver for circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
4.  Continuing education.  By December 31, 2017, an individual licensed under this 
chapter must successfully complete 3 hours of continuing education every 2 years on the 
prescription of opioid medication as a condition of prescribing opioid medication.  The 
board shall adopt rules to implement this subsection.  Rules adopted pursuant to this 
subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
5.  Penalties.  An individual who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged.  The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 14.  32 MRSA §2591-A, sub-§2, ¶M, as amended by PL 1997, c. 680, Pt. B, 
§6, is further amended to read: 
M.  Failure to comply with the requirements of Title 24, section 2905-A; or 
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Sec. 15.  32 MRSA §2591-A, sub-§2, ¶N, as enacted by PL 1997, c. 680, Pt. B, 
§7, is amended to read: 
N.  Revocation, suspension or restriction of a license to practice medicine or other 
disciplinary action; denial of an application for a license; or surrender of a license to 
practice medicine following the institution of disciplinary action by another state or a 
territory of the United States or a foreign country if the conduct resulting in the 
disciplinary or other action involving the license would, if committed in this State, 
constitute grounds for discipline under the laws or rules of this State.; or 
Sec. 16.  32 MRSA §2591-A, sub-§2, ¶O is enacted to read: 
O.  Failure to comply with the requirements of Title 22, section 7253. 
Sec. 17.  32 MRSA §2600-C is enacted to read: 
§2600-C.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  Except as provided in subsection 2, 
an individual licensed under this chapter whose scope of practice includes prescribing 
opioid medication may not prescribe: 
A.  To a patient any combination of opioid medication in an aggregate amount in 
excess of 100 morphine milligram equivalents of opioid medication per day; 
B.  To a patient who, on the effective date of this section, has an active prescription 
for opioid medication in excess of 100 morphine milligram equivalents of an opioid 
medication per day, an opioid medication in an amount that would cause that patient's 
total amount of opioid medication to exceed 300 morphine milligram equivalents of 
opioid medication per day; except that, on or after July 1, 2017, the aggregate amount 
of opioid medication prescribed may not be in excess of 100 morphine milligram 
equivalents of opioid medication per day; 
C.  On or after January 1, 2017, within a 30-day period, more than a 30-day supply of 
an opioid medication to a patient under treatment for chronic pain.  For purposes of 
this paragraph, "chronic pain" has the same meaning as in Title 22, section 7246, 
subsection 1-C; or 
D.  On or after January 1, 2017, within a 7-day period, more than a 7-day supply of 
an opioid medication to a patient under treatment for acute pain.  For purposes of this 
paragraph, "acute pain" has the same meaning as in Title 22, section 7246, subsection 
1-A. 
2.  Exceptions.  An individual licensed under this chapter whose scope of practice 
includes prescribing opioid medication is exempt from the limits on opioid medication 
prescribing established in subsection 1 only: 
A.  When prescribing opioid medication to a patient for: 
(1)  Pain associated with active and aftercare cancer treatment; 
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(2)  Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph 
A, in conjunction with a serious illness, as defined in Title 22, section 1726, 
subsection 1, paragraph B; 
(3)  End-of-life and hospice care; 
(4)  Medication-assisted treatment for substance use disorder; or 
(5)  Other circumstances determined in rule by the Department of Health and 
Human Services pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering or administering a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility. 
As used in this paragraph, "administer" has the same meaning as in Title 22, section 
7246, subsection 1-B. 
3.  Electronic prescribing.  An individual licensed under this chapter whose scope of 
practice includes prescribing opioid medication and who has the capability to 
electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  An individual who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver for circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
4.  Continuing education.  By December 31, 2017, an individual licensed under this 
chapter must successfully complete 3 hours of continuing education every 2 years on the 
prescription of opioid medication as a condition of prescribing opioid medication.  The 
board shall adopt rules to implement this subsection.  Rules adopted pursuant to this 
subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
5.  Penalties.  An individual who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged.  The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 18.  32 MRSA §3282-A, sub-§2, ¶¶Q and R, as enacted by PL 2013, c. 
355, §12, are amended to read: 
Q.  Failure to produce upon request of the board any documents in the licensee's 
possession or under the licensee's control concerning a pending complaint or 
proceeding or any matter under investigation by the board, unless otherwise 
prohibited by state or federal law; or 
R.  Failure to timely respond to a complaint notification sent by the board.; or 
Sec. 19.  32 MRSA §3282-A, sub-§2, ¶S is enacted to read: 
S.  Failure to comply with the requirements of Title 22, section 7253. 
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Sec. 20.  32 MRSA §3300-F is enacted to read: 
§3300-F.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  Except as provided in subsection 2, 
an individual licensed under this chapter and whose scope of practice includes prescribing 
opioid medication may not prescribe: 
A.  To a patient any combination of opioid medication in an aggregate amount in 
excess of 100 morphine milligram equivalents of opioid medication per day; 
B.  To a patient who, on the effective date of this section, has an active prescription 
for opioid medication in excess of 100 morphine milligram equivalents of an opioid 
medication per day, an opioid medication in an amount that would cause that patient's 
total amount of opioid medication to exceed 300 morphine milligram equivalents of 
opioid medication per day; except that, on or after July 1, 2017, the aggregate amount 
of opioid medication prescribed may not be in excess of 100 morphine milligram 
equivalents of opioid medication per day; 
C.  On or after January 1, 2017, within a 30-day period, more than a 30-day supply of 
an opioid medication to a patient under treatment for chronic pain.  "Chronic pain" 
has the same meaning as in Title 22, section 7246, subsection 1-C; or 
D.  On or after January 1, 2017, within a 7-day period, more than a 7-day supply of 
an opioid medication to a patient under treatment for acute pain.  "Acute pain" has the 
same meaning as in Title 22, section 7246, subsection 1-A. 
2.  Exceptions.  An individual licensed under this chapter whose scope of practice 
includes prescribing opioid medication is exempt from the limits on opioid medication 
prescribing established in subsection 1 only: 
A.  When prescribing opioid medication to a patient for: 
(1)  Pain associated with active and aftercare cancer treatment; 
(2)  Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph 
A, in conjunction with a serious illness, as defined in Title 22, section 1726, 
subsection 1, paragraph B; 
(3)  End-of-life and hospice care; 
(4)  Medication-assisted treatment for substance use disorder; or 
(5)  Other circumstances determined in rule by the Department of Health and 
Human Services pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering or administering a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility. 
As used in this paragraph, "administer" has the same meaning as in Title 22, section 
7246, subsection 1-B. 
3.  Electronic prescribing.  An individual licensed under this chapter and whose 
scope of practice includes prescribing opioid medication with the capability to 
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electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  An individual who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure, and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver including circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
4.  Continuing education.  By December 31, 2017, an individual licensed under this 
chapter must successfully complete 3 hours of continuing education every 2 years on the 
prescription of opioid medication as a condition of prescribing opioid medication.  The 
board shall adopt rules to implement this subsection.  Rules adopted pursuant to this 
subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
5.  Penalties.  An individual who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged.  The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 21.  32 MRSA §3656, sub-§§3 and 4, as enacted by PL 2007, c. 402, Pt. P, 
§14, are amended to read: 
3.  False advertising.  Engaging in false, misleading or deceptive advertising; or 
4.  Unlawful prescription of controlled substance.  Prescribing narcotic or hypnotic 
or other drugs listed as controlled substances by the federal Drug Enforcement 
Administration for other than accepted therapeutic purposes.; or 
Sec. 22.  32 MRSA §3656, sub-§5 is enacted to read: 
5.  Controlled Substances Prescription Monitoring Program.  Failure to comply 
with the requirements of Title 22, section 7253. 
Sec. 23.  32 MRSA §3657 is enacted to read: 
§3657.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  Except as provided in subsection 2, 
an individual licensed under this chapter and whose scope of practice includes prescribing 
opioid medication may not prescribe: 
A.  To a patient any combination of opioid medication in an aggregate amount in 
excess of 100 morphine milligram equivalents of opioid medication per day; 
B.  To a patient who, on the effective date of this section, has an active prescription 
for opioid medication in excess of 100 morphine milligram equivalents of an opioid 
medication per day, an opioid medication in an amount that would cause that patient's 
total amount of opioid medication to exceed 300 morphine milligram equivalents of 
opioid medication per day; except that, on or after July 1, 2017, the aggregate amount 
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of opioid medication prescribed may not be in excess of 100 morphine milligram 
equivalents of opioid medication per day; 
C.  On or after January 1, 2017, within a 30-day period, more than a 30-day supply of 
an opioid medication to a patient under treatment for chronic pain.  "Chronic pain" 
has the same meaning as in Title 22, section 7246, subsection 1-C; or 
D.  On or after January 1, 2017, within a 7-day period, more than a 7-day supply of 
an opioid medication to a patient under treatment for acute pain.  "Acute pain" has the 
same meaning as in Title 22, section 7246, subsection 1-A. 
2.  Exceptions.  An individual licensed under this chapter whose scope of practice 
includes prescribing opioid medication is exempt from the limits on opioid medication 
prescribing established in subsection 1 only: 
A.  When prescribing opioid medication to a patient for: 
(1)  Pain associated with active and aftercare cancer treatment; 
(2)  Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph 
A, in conjunction with a serious illness, as defined in Title 22, section 1726, 
subsection 1, paragraph B; 
(3)  End-of-life and hospice care; 
(4)  Medication-assisted treatment for substance use disorder; or 
(5)  Other circumstances determined in rule by the Department of Health and 
Human Services pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering or administering a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility. 
As used in this paragraph, "administer" has the same meaning as in Title 22, section 
7246, subsection 1-B. 
3.  Electronic prescribing.  An individual licensed under this chapter and whose 
scope of practice includes prescribing opioid medication with the capability to 
electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  An individual who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure, and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver including circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
4.  Continuing education.  By December 31, 2017, an individual licensed under this 
chapter must successfully complete 3 hours of continuing education every 2 years on the 
prescription of opioid medication as a condition of prescribing opioid medication.  The 
board shall adopt rules to implement this subsection.  Rules adopted pursuant to this 
subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
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5.  Penalties.  An individual who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged.  The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 24.  32 MRSA §4864, sub-§12, ¶D, as amended by PL 2007, c. 402, Pt. R, 
§8, is further amended to read: 
D.  The continuance of a veterinarian directly or indirectly in the employ of or in 
association with any veterinarian after knowledge that such veterinarian is engaged in 
the violation of the provisions of this chapter; or 
Sec. 25.  32 MRSA §4864, sub-§13, as amended by PL 2007, c. 402, Pt. R, §8, is 
further amended to read: 
13.  Lack of sanitation. Failure to maintain veterinary premises and equipment in a 
clean and sanitary condition as defined by the board in accordance with the sanitation 
provisions included in Title 7, section 3936.; or 
Sec. 26.  32 MRSA §4864, sub-§15 is enacted to read: 
15.  Controlled Substances Prescription Monitoring Program.  Failure to comply 
with the requirements of Title 22, section 7253. 
Sec. 27.  32 MRSA §4878 is enacted to read: 
§4878.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  A veterinarian licensed under this 
chapter whose scope of practice includes prescribing opioid medication to an animal is 
subject to the requirements of the Controlled Substances Prescription Monitoring 
Program established under Title 22, chapter 1603, except that Title 22, section 7254 does 
not apply. 
2.  Electronic prescribing.  A veterinarian licensed under this chapter whose scope 
of practice includes prescribing opioid medication and who has the capability to 
electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  A veterinarian who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver for circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
3.  Continuing education.  By December 31, 2017, a veterinarian who prescribes 
opioid medication must successfully complete 3 hours of continuing education every 2 
years on the prescription of opioid medication as a condition of prescribing opioid 
medication.  The board shall adopt rules to implement this subsection.  Rules adopted 
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pursuant to this subsection are routine technical rules as defined in Title 5, chapter 375, 
subchapter 2-A. 
4.  Penalties.  A veterinarian who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged. The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 28.  32 MRSA §13702-A, sub-§20-A is enacted to read: 
20-A.  Opioid medication.  "Opioid medication" means a controlled substance 
containing an opioid included in schedule II of 21 United States Code, Section 812 or 21 
Code of Federal Regulations, Part 1308. 
Sec. 29.  32 MRSA §13756 is enacted to read: 
§13756.  Electronic prescribing of opioid medication 
By July 1, 2017, a pharmacy must have the capability to process electronic 
prescriptions from prescribers for an opioid medication or request a waiver from the 
Commissioner of Health and Human Services stating the reasons for the waiver including 
but not limited to a lack of capability, the availability of broadband infrastructure and a 
plan for developing the ability to receive electronically prescribed opioid medication.  
The commissioner may grant a waiver for circumstances in which exceptions are 
appropriate, including technological failures. 
Sec. 30.  32 MRSA §13786-B is enacted to read: 
§13786-B.  Partial dispensing of prescription for opioid medication 
1.  Partial dispensing authorized.  Notwithstanding any law or rule to the contrary, 
a pharmacist may partially dispense a prescription for an opioid medication in a lesser 
quantity than the recommended full quantity indicated on the prescription if requested by 
the patient for whom the prescription is written.  The remaining quantity of the 
prescription in excess of the recommended full quantity is void and may not be dispensed 
without a new prescription. 
2.  Notice to practitioner.  If a pharmacist partially dispenses a prescription for an 
opioid medication as permitted under this section, the pharmacist or the pharmacist's 
designee shall, within a reasonable time following the partial dispensing but not more 
than 7 days, notify the practitioner of the quantity of the opioid medication actually 
dispensed.  The notice may be conveyed by a notation on the patient's electronic health 
record or by electronic transmission, by facsimile or by telephone to the practitioner. 
Sec. 31.  32 MRSA §13786-C is enacted to read: 
§13786-C.  Dispensing of prescription of opioid medication; immunity 
A pharmacist who dispenses opioid medication in good faith is immune from any 
civil liability that might otherwise result from dispensing medication in excess of the 
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limit established in section 2210, subsection 1, paragraphs A and B; section 2600-C, 
subsection 1, paragraphs A and B; section 3300-F, subsection 1, paragraphs A and B; 
section 3657, subsection 1, paragraphs A and B; or section 18308, subsection 1, 
paragraphs A and B, if the medication was dispensed in accordance with a prescription 
issued by a practitioner.  In a proceeding regarding immunity from liability, there is a 
rebuttable presumption of good faith. 
Sec. 32.  32 MRSA §18308 is enacted to read: 
§18308.  Requirements regarding prescription of opioid medication 
1.  Limits on opioid medication prescribing.  Except as provided in subsection 2, 
an individual licensed under this chapter whose scope of practice includes prescribing 
opioid medication may not prescribe: 
A.  To a patient any combination of opioid medication in an aggregate amount in 
excess of 100 morphine milligram equivalents of opioid medication per day; 
B.  To a patient who, on the effective date of this section, has an active prescription 
for opioid medication in excess of 100 morphine milligram equivalents of an opioid 
medication per day, an opioid medication in an amount that would cause that patient's 
total amount of opioid medication to exceed 300 morphine milligram equivalents of 
opioid medication per day; except that, on or after July 1, 2017, the aggregate amount 
of opioid medication prescribed may not be in excess of 100 morphine milligram 
equivalents of opioid medication per day; 
C.  On or after January 1, 2017, within a 30-day period, more than a 30-day supply of 
an opioid medication to a patient under treatment for chronic pain.  For purposes of 
this paragraph, "chronic pain" has the same meaning as in Title 22, section 7246, 
subsection 1-C; or 
D.  On or after January 1, 2017, within a 7-day period, more than a 7-day supply of 
an opioid medication to a patient under treatment for acute pain.  For purposes of this 
paragraph, "acute pain" has the same meaning as in Title 22, section 7246, subsection 
1-A. 
2.  Exceptions.  An individual licensed under this chapter whose scope of practice 
includes prescribing opioid medication is exempt from the limits on opioid medication 
prescribing established in subsection 1 only: 
A.  When prescribing opioid medication to a patient for: 
(1)  Pain associated with active and aftercare cancer treatment; 
(2)  Palliative care, as defined in Title 22, section 1726, subsection 1, paragraph 
A, in conjunction with a serious illness, as defined in Title 22, section 1726, 
subsection 1, paragraph B; 
(3)  End-of-life and hospice care; 
(4)  Medication-assisted treatment for substance use disorder; or 
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(5)  Other circumstances determined in rule by the Department of Health and 
Human Services pursuant to Title 22, section 7254, subsection 2; and 
B.  When directly ordering or administering a benzodiazepine or opioid medication to 
a person in an emergency room setting, an inpatient hospital setting, a long-term care 
facility or a residential care facility. 
As used in this paragraph, "administer" has the same meaning as in Title 22, section 
7246, subsection 1-B. 
3.  Electronic prescribing.  An individual licensed under this chapter whose scope of 
practice includes prescribing opioid medication and who has the capability to 
electronically prescribe shall prescribe all opioid medication electronically by July 1, 
2017.  An individual who does not have the capability to electronically prescribe must 
request a waiver from this requirement from the Commissioner of Health and Human 
Services stating the reasons for the lack of capability, the availability of broadband 
infrastructure and a plan for developing the ability to electronically prescribe opioid 
medication.  The commissioner may grant a waiver for circumstances in which 
exceptions are appropriate, including prescribing outside of the individual's usual place of 
business and technological failures. 
4.  Continuing education.  By December 31, 2017, an individual licensed under this 
chapter must successfully complete 3 hours of continuing education every 2 years on the 
prescription of opioid medication as a condition of prescribing opioid medication.  The 
board shall adopt rules to implement this subsection.  Rules adopted pursuant to this 
subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
5.  Penalties.  An individual who violates this section commits a civil violation for 
which a fine of $250 per violation, not to exceed $5,000 per calendar year, may be 
adjudged.  The Department of Health and Human Services is responsible for the 
enforcement of this section. 
Sec. 33.  32 MRSA §18325, sub-§1, ¶¶N and O, as enacted by PL 2015, c. 429, 
§21, are amended to read: 
N.  Any violation of a requirement imposed pursuant to section 18352; and 
O.  A violation of this chapter or a rule adopted by the board.; and 
Sec. 34.  32 MRSA §18325, sub-§1, ¶P is enacted to read: 
P.  Failure to comply with the requirements of Title 22, section 7253. 
Sec. 35.  Department of Health and Human Services to amend rules to 
require registration of pharmacists; automatic enrollment.  The Department of 
Health and Human Services shall amend its rules governing the Controlled Substances 
Prescription Monitoring Program under the Maine Revised Statutes, Title 22, chapter 
1603 no later than January 1, 2017 to require pharmacists to register as data requesters.  
The enrollment mechanism for pharmacists who are registering with the program or 
renewing registration must be automatic when applying for or renewing a professional 
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license in the same manner as it is for prescribers who are health care professionals with 
authority to prescribe controlled substances. 
Sec. 36.  Department of Health and Human Services to amend rules to 
require registration of veterinarians; automatic enrollment.  The Department of 
Health and Human Services shall amend its rules governing the Controlled Substances 
Prescription Monitoring Program under the Maine Revised Statutes, Title 22, chapter 
1603 no later than January 1, 2017 to require veterinarians to register as data requesters.  
The enrollment mechanism for veterinarians who are registering with the program or 
renewing registration must be automatic when applying for or renewing a professional 
license in the same manner as it is for prescribers who are health care professionals with 
authority to prescribe controlled substances. 
Sec. 37.  Enhancements to the Controlled Substances Prescription 
Monitoring Program.  The Department of Health and Human Services shall include in 
its request for proposals process under the Maine Revised Statutes, Title 22, section 7248, 
subsection 2 the following enhancements to the Controlled Substances Prescription 
Monitoring Program under Title 22, chapter 1603: 
1.  A mechanism or calculator for converting dosages to and from morphine 
milligram equivalents; 
2.  A mechanism to automatically transmit de-identified peer data on an annual basis 
to prescribers of opioid medication; 
3.  Allowance for a broader authorization for staff members of prescribers to access 
the program including a single annual authorization for staff members at a licensed 
hospital and a pharmacy; 
4.  Improvements in communication regarding the ability of a prescriber to authorize 
staff members to access the program on behalf of the prescriber; 
5.  Improvements in communication regarding the ability of a pharmacist to authorize 
staff members to access the program on behalf of the pharmacist; 
6.  Improvements in the speed of the program for prescribers and pharmacists 
required to submit information and check the program, and the ability for prescribers and 
pharmacists to tailor the functions of the program to fit into the workflow of the 
prescribers and pharmacists required to access the program; and 
7.  The establishment of a data modifier for information from a veterinarian 
prescribing opioid medication to an animal that differentiates the recipient of the opioid 
prescription from people. 
Notwithstanding the Title 32, section 2210, subsection 5; section 2600-C, subsection 
5; section 3300-F, subsection 5; section 3657, subsection 5; and section 18308, 
subsection 5, a penalty may not be imposed for a violation of the limits on opioid 
prescribing in Title 32, section 2210, subsection 1; section 2600-C, subsection 1; section 
3300-F, subsection 1; section 3657, subsection 1; or section 18308, subsection 1 until the 
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enhancement to the Controlled Substances Prescription Monitoring Program described in 
subsection 1 is implemented. 
Sec. 38.  Effect on out-of-pocket costs.  The Bureau of Insurance within the 
Department of Professional and Financial Regulation shall evaluate the effect of the 
limits on prescriptions for opioid medication established by this Act on the claims paid by 
health insurance carriers and the out-of-pocket costs, including copayments, coinsurance 
and deductibles, paid by individual and group health insurance policyholders.  On or 
before January 1, 2018, the bureau shall submit a report on the evaluation, along with any 
recommended policy and regulatory options that will ensure costs for patients are not 
increased as a result of new prescribing limitations on the amounts of opioid medications, 
to the joint standing committees of the Legislature having jurisdiction over health and 
human services matters and over insurance and financial services matters.  The joint 
standing committee of the Legislature having jurisdiction over health and human services 
matters and the joint standing committee of the Legislature having jurisdiction over 
insurance and financial services matters may report out legislation related to the 
evaluation to the Second Regular Session of the 128th Legislature.  
Sec. 39.  Department of Health and Human Services implementation 
report.  The Department of Health and Human Services shall report to the joint standing 
committees of the Legislature having jurisdiction over health and human services matters 
and over occupational and professional regulation matters, no later than January 31, 2018, 
with progress on implementing the provisions of this Act.  The report must contain 
information on the following: 
1.  Registration of prescribers and dispensers in the Controlled Substances 
Prescription Monitoring Program under the Maine Revised Statutes, Title 22, chapter 
1603; 
2.  Data regarding the checking and using of the Controlled Substances Prescription 
Monitoring Program by data requesters; 
3.  Data from professional boards regarding the implementation of continuing 
education requirements for prescribers of opioid medication; 
4.  Effects on the prescriber workforce; 
5.  Changes in the numbers of patients taking more than 100 morphine milligram 
equivalents of opioid medication per day; 
6.  Data regarding the total number of opioid medication pills prescribed; 
7.  Progress on electronic prescribing of opioid medication; and 
8.  Improvements to the Controlled Substances Prescription Monitoring Program 
through the request for proposals process including feedback from prescribers and 
dispensers on those improvements. 
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APPENDIX 2
MHDO Data Request #811165 - Maine Bureau of Insurance
Instance Number 2017041401
Opioid Rx Summary Ad Hoc
Table 1 Opioid Prescription Summary
Unduplicated Count of 
Pharmacy Members 
with Rx Claims
Unduplicated Count of 
Pharmacy Members w/ 
Opioid Rx
Unduplicated Count of 
Opioid Rx Claims
Unduplicated Count of 
Opioid Scripts Total Plan Paid Total Member Paid
Q1 2016 337,767 34,056 75,466 75,545 $2,811,997.42 $923,758.74
Q2 2016 302,495 29,727 64,300 64,302 $2,444,551.02 $644,609.79
Overall Q1 & 2 2016 393,434 51,253 139,754 139,835 $5,256,548.44 $1,568,368.53
Q1 2017 300,359 26,512 58,631 58,633 $1,452,072.35 $555,736.52
Q2 2017 293,394 24,091 53,389 53,389 $1,351,184.42 $433,248.11
Overall Q1 & 2 2017 354,232 40,591 112,015 112,018 $2,803,256.77 $988,984.63
Overall Total 494,524 78,856                               252,130                               252,214 $8,059,805.21 $2,557,353.16
Notes: Q1 2016 included 9 months 
runout. Q2 2016 included 6 months 
runout. Q1 2017 included 3 months 
runout. Q2 2017 included no 
runout. 2016 data were not 
updated from original report.
Appendix 3 
Payer Names w/ Opioid Rx Claims 
Aetna Health Inc  
Aetna Health Inc  
Aetna Life Insurance Company  
American Health Care Administrative Services Inc  
Anthem Health Plans of Maine Inc  
CaremarkPCS Health LLC  
Cigna Health and Life Insurance Company  
Cigna Health and Life Insurance Company  
Comprehensive Benefits Administrator Inc  
EBPA Benefits, LLC  
Envision Pharmaceutical Services, LLC  
Express Scripts Administrators, LLC  
Geisinger Indemnity Insurance Company  
Harvard Pilgrim Health Care  
Harvard Pilgrim Insurance Company  
Health Care Service Corporation  
Health Care Service Corporation  
Humana Insurance Company  
Maine Community Health Options  
OptumRx, Inc.  
Prime Therapeutics LLC  
UMR Inc  
UnitedHealthcare Insurance Company  
UnitedHealthcare Services Inc  
 
